Laboratorios Farmaceuticos Rovi, S.A. (BIT:1ROVI)

Market Cap	3.13B
Revenue (ttm)	749.00M
Net Income (ttm)	132.27M
Shares Out	n/a
EPS (ttm)	2.59
PE Ratio	23.63
Forward PE	21.86
Dividend	0.76 (1.29%)
Ex-Dividend Date	Jul 14, 2025

Volume	n/a
Average Volume	15
Open	65.05
Previous Close	65.05
Day's Range	65.05 - 65.05
52-Week Range	45.95 - 66.35
Beta	n/a
RSI	60.32
Earnings Date	Nov 6, 2025

About BIT:1ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ROVI

Financial Performance

In 2024, BIT:1ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.